Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved its biosimilar to Amgen’s AMGN blockbuster drug, Prolia (denosumab). The biosimilar will be available in the United States ...

The US Food and Drug Administration (:FDA) recently granted approval to Amgen’s (AMGN) Prolia (denosumab) for an additional indication. Prolia can now be used as a treatment for increasing bone mass ...

Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s ...

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

The FINANCIAL — Amgen on July 31 announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia (denosumab) for the treatment ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.

AmgenAMGN crushed third-quarter expectations late Tuesday, thanks to big sales beats from blockbuster drugs Repatha and Prolia. Revenue from cholesterol treatment Repatha surged 40% to $794 million, ...

LOS ANGELES (Reuters) - A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.